Crescent Biopharma, Inc. (CBIO) fair value analysis
Nasdaq · Updated 2026-10-19
CBIO price how computed
Valuation status
No fair-value estimate yetCBIO has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for CBIO yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $11.84
- Sector
- Healthcare
- 12-month range
- $8.94–$26.98
- Market cap
- $440M
- From 52-week high
- -56.1%
- Shares outstanding
- 37.1M
- Rank in Healthcare by quality score
- #226 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Crescent Biopharma, Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapeutic products for treating serious diseases. The company operates primarily in the United States and engages in research and development activities within the healthcare sector.
CBIO currently ranks #226 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $440M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $42.4M
- Net margin
- -384.0%
- EPS (TTM)
- $-6.82
- Debt / equity
- 0.01
- Shares outstanding
- 37.1M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 24 · oversold
- 50-day average
- $16.37
- 200-day average
- $15.79
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2023-01-13)
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▲ beat (+5.1%)
2026-03 ▲ beat (+11.0%)
2025-12 ▼ miss (-80.6%)
2025-09 ▲ beat (+0.7%)
2025-06 ▼ miss (-1.1%)
2025-03 ▼ miss (-405.2%)
2024-12 ▲ beat (+11.1%)
2024-09 ▼ miss (-13750.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 1 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $31.5
- Target vs last price
- +166.0%
What our data shows for CBIO
- Shares are trading in the lower third of their 12-month price range of $8.94–$26.98.
- The 14-day relative strength index sits at an oversold 24.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- CBIO's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the CBIO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for CBIO showed a shift this week, with the RSI zone moving from neutral into oversold territory. The stock remains in the Healthcare sector with a valuation verdict of awaiting full valuation. This oversold reading suggests the stock price has declined significantly over the recent period relative to its recent trading range.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is CBIO stock undervalued?
TickrTrends has no fair-value estimate for CBIO yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is CBIO's TickrTrends verdict?
CBIO is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does CBIO compare to other Healthcare stocks?
CBIO ranks #226 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is CBIO overbought or oversold?
CBIO's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
Does CBIO pay a dividend?
CBIO has paid no dividend in the last twelve months; its last ex-dividend date on file was 2023-01-13.
When does CBIO report earnings next?
CBIO's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does CBIO usually beat earnings estimates?
Over its last 8 reported quarters CBIO beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CBIO?
Of 8 analysts covering CBIO, 7 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $31.5 (+166.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.